Eviplera
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neurocognitive Decline
Conditions
Neurocognitive Decline, HIV Associated Neurocognitive Disorder
Trial Timeline
Feb 1, 2015 → Jun 1, 2017
NCT ID
NCT02308332About Eviplera
Eviplera is a approved stage product being developed by Gilead Sciences for Neurocognitive Decline. The current trial status is completed. This product is registered under clinical trial identifier NCT02308332. Target conditions include Neurocognitive Decline, HIV Associated Neurocognitive Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02529059 | Approved | Completed |
| NCT02308332 | Approved | Completed |
Competing Products
1 competing product in Neurocognitive Decline
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atorvastatin | Pfizer | Pre-clinical | 22 |